Mary Jo Fidler, MD

Name: Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum
Start: 2025-09-07T18:30:00+02:00
End: 2025-09-07T19:30:00+02:00

February 12, 2021

|

By

|

Estimated Read Time:

1 minute

Names & News

Mary Jo Fidler, MD, is now Section Chief for Section of Medical Oncology at Rush Medical College. She has been on staff in medical oncology at RUSH since 2007. Dr. Fidler is a member of both the Communications Committee and ILCN Editorial Group.

About the Authors

Share this Article:

Mary Jo Fidler, MD

Recent Posts

World Conference Conversations: Inside WCLC 2025

Opening Plenary to Highlight Significant Achievements in Thoracic Oncology

Third Annual Amazing Case Race Returns for WCLC 2025

Preconference Workshops Offer Diverse Educational Opportunities Across Specialties

IS03: Satellite EBAC/CME Symposium by Answers in CME: Reshaping the Management of Metastatic NSCLC: Tackling HER2 Overexpression to Elevate Outcomes

Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC